expresspharmaAugust 07, 2020
Tag: Novavax , COVID-19 vaccine , Serum Institute of India
Novavax has entered a supply and license agreement with the Serum Institute of India for the development and commercialisation of its COVID-19 vaccine candidate.
Serum Institute of India will have exclusive rights for the vaccine in India during the term of the deal and non-exclusive rights during the “pandemic period” in all countries other than those designated by the World Bank as upper-middle or high-income countries.
The deal was signed on July 30, according to an SEC filing by Novavax.
Recently, Novavax reported that its experimental COVID-19 vaccine produced high levels of antibodies against the novel coronavirus in a small, early-stage clinical trial and that it could start a large pivotal Phase III trial as soon as late September.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: